Pharmaceutical

Lava signs collaboration agreement with MSD for prostate cancer therapy

MSD will supply Keytruda to be evaluated as a combination treatment with Lava’s LAVA-1207 in an ongoing Phase I/IIa study.

Jan 25, 2024 - 18:00
Lava signs collaboration agreement with MSD for prostate cancer therapy
MSD will supply Keytruda to be evaluated as a combination treatment with Lava’s LAVA-1207 in an ongoing Phase I/IIa study.
Read the original article

Tags:

Previous Article

STAT+: Sanofi scoops up U.S. biotech Inhibrx for up to $2.2 billion as it seeks ...

Next Article

Repare bags $40m from Roche as solid tumour trial begins

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ardelyx sues CMS over revamped kidney disease drug payment bundle

Ardelyx sues CMS over revamped kidney disease drug paym...

Jul 20, 2024

A rational design approach to RNA targeting could replace large-scale screening

A rational design approach to RNA targeting could repla...

Oct 6, 2024

STAT+: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more

STAT+: Pharmalittle: We’re reading about Congress punts...

Feb 27, 2024